Related Experiment Video
Updated: Feb 28, 2026
Preparation of Rat Oligodendrocyte Progenitor Cultures and Quantification of Oligodendrogenesis Using Dual-infrared Fluorescence Scanning
Published on: February 17, 2016
Protecting Oligodendrocytes by Targeting Non-Glutamate Receptors as a New Therapeutic Strategy for Ischemic Stroke
Pan Luo1, Dong Liu, Lianjun Guo
1Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Abstract:
Ischemic stroke has many devastating effects within the brain. At the cellular level, excitotoxicity has been a popular pharmacological target for therapeutics. To date, many clinical trials have been performed with drugs that target excitatory neurotransmitter receptors, such as NMDA receptor agonists. The results, however, have been lackluster. Most efforts to understand the impacts of excitotoxicity on the brain have focused primarily on neurons, and to a lesser degree, on gliocytes as cellular targets. Recent evidence suggests that oligodendrocytes (OLGs), the myelin-forming cells in the central nervous system, are damaged by ischemia in a manner completely different from that in neurons. Whereas ischemia primarily damages neurons through overactivation of ionotropic glutamate receptors, the ischemia damage in OLGs occurs through overactivation of H+-gated transient receptor potential channels. Given the differential mechanisms of ischemic injury between neurons and OLGs, strategies to target non-glutamate receptors to prevent OLG damage/demyelination deserve greater attention in drug development. Such strategies, combined with neuroprotective measures, could provide an excellent therapeutic avenue for the treatment of ischemic stroke.
Insights
Ischemic stroke damages brain cells differently. Targeting H+-gated channels, not just glutamate receptors, may protect oligodendrocytes and prevent demyelination, offering new therapeutic strategies.
Area of Science:
- Neuroscience
- Cellular Biology
- Pharmacology
Background:
- Ischemic stroke causes significant brain damage.
- Excitotoxicity, targeting glutamate receptors, has been a focus for stroke therapeutics with limited success.
- Oligodendrocytes (OLGs) are uniquely vulnerable to ischemic injury via different mechanisms than neurons.
Purpose of the Study:
- To investigate the distinct mechanisms of ischemic injury in oligodendrocytes compared to neurons.
- To highlight the potential of targeting non-glutamate receptors for oligodendrocyte protection.
- To propose novel therapeutic strategies for ischemic stroke treatment.
Main Methods:
- Review of recent evidence on cellular mechanisms of ischemic brain injury.
- Analysis of differential cellular responses to ischemia in neurons and oligodendrocytes.
- Exploration of pharmacological targets beyond ionotropic glutamate receptors.
Main Results:
- Ischemia damages neurons primarily through excitotoxicity via glutamate receptors.
- Ischemia damages oligodendrocytes through overactivation of H+-gated transient receptor potential channels.
- Oligodendrocytes exhibit distinct vulnerability pathways during ischemic stroke.
Conclusions:
- Targeting H+-gated channels offers a promising therapeutic avenue for preventing oligodendrocyte damage and demyelination.
- Developing strategies that protect oligodendrocytes, in addition to neuroprotective measures, could improve ischemic stroke treatment outcomes.
- Non-glutamate receptor-based therapies warrant further investigation for ischemic stroke drug development.
More Related Videos
Related Concept Videos
01:30Ligand-Gated Ion Channel Receptor: Gating Mechanism
01:14Antiepileptic Drugs: Glutamate Antagonists